. 2019 May 9;8(6):754–763. doi: 10.1530/EC-19-0045
This work is licensed under a Table 4.
Comparison of various clinicopathologic features between patients with bilateral and unilateral papillary thyroid carcinoma.
| Variable | Bilateral PTCs group | Unilateral PTCs group | P value |
|---|---|---|---|
| Number (%) of patients | 418 (34.3) | 802 (65.7) | |
| Sex, n (%) | 0.008* | ||
| Male | 113 (27.0) | 277 (34.5) | |
| Female | 305 (73.0) | 525 (65.5) | |
| Age at diagnosis (years), mean ± s.d. | 39.3 ± 12.0 | 38.3 ± 12.5 | 0.186 |
| Family history | 0.947 | ||
| Yes | 21 (5.0) | 41 (5.1) | |
| No | 397 (95.0) | 761 (94.9) | |
| Histologic variants, n (%) | 0.209 | ||
| Classic PTC | 401 (95.9) | 767 (95.6) | |
| Follicular variant PTC | 9 (2.2) | 27 (3.4) | |
| Other aggressive variants PTCa | 8 (1.9) | 8 (1.0) | |
| Tumor sizeb, cm | 0.289 | ||
| Mean ± s.d. | 1.73 ± 1.24 | 1.66 ± 1.06 | |
| Range | 0.20-9.00 | 0.08-10.00 | |
| Tumor size, n (%) | 0.298 | ||
| ≤1 cm | 128 (30.6) | 259 (32.3) | |
| 1–2 cm | 199 (47.6) | 355 (44.3) | |
| 2–4 cm | 74 (17.7) | 166 (20.7) | |
| 4 cm | 17 (4.1) | 22 (2.7) | |
| Capsular invasion, n (%) | 0.048* | ||
| Yes | 304 (72.7) | 539 (67.2) | |
| No | 114 (27.3) | 263 (32.8) | |
| Extrathyroidal invasion, n (%) | 0.002* | ||
| Yes | 262 (62.7) | 427 (53.2) | |
| No | 156 (37.3) | 375 (46.8) | |
| Vascular invasion, n (%) | 0.229 | ||
| Yes | 50 (12.0) | 78 (9.7) | |
| No | 368 (88.0) | 723 (90.3) | |
| Neurological invasion, n (%) | 0.882 | ||
| Yes | 27 (6.5) | 50 (6.2) | |
| No | 391 (93.5) | 751 (93.8) | |
| Gross extrathyroidal extension, n (%) | 0.120 | ||
| Yes | 127 (30.4) | 210 (26.2) | |
| No | 291 (69.6) | 592 (73.8) | |
| With Hashimoto thyroiditis, n (%) | 0.783 | ||
| Yes | 101 (24.2) | 200 (24.9) | |
| No | 316 (75.8) | 602 (75.1) | |
| With nodular goiter, n (%) | <0.001* | ||
| Yes | 135 (32.4) | 360 (44.9) | |
| No | 282 (67.6) | 442 (55.1) | |
| Lymph node metastases (LNs)c, n (%) | 0.695 | ||
| Yes | 374 (89.5) | 728 (90.8) | |
| No | 25 (6.0) | 39 (4.9) | |
| No neck dissection | 19 (4.5) | 35 (4.4) | |
| Extracapsular extension of metastatic lymph nodes, n (%) | 0.132 | ||
| Yes | 166 (45.2) | 288 (40.4) | |
| No | 201 (54.8) | 424 (59.6) | |
| Fusion of metastatic lymph nodes, n (%) | 0.009* | ||
| Yes | 47 (12.8) | 56 (7.9) | |
| No | 320 (87.2) | 656 (92.1) | |
| ATA risk stratification, n (%) | 0.112 | ||
| Intermediate | 277 (66.3) | 567 (70.7) | |
| High | 141 (33.7) | 235 (29.3) | |
| The 8th AJCC TNM stage, n (%) | 0.874 | ||
| I/II | 400 (95.7) | 769 (95.9) | |
| III/IV | 18 (4.3) | 33 (4.1) |
aOther aggressive variants include oxyphilic, diffuse sclerosing, solid variant. bTumor size is recorded as the greatest tumor dimension. cLymph node metastasis at the completion of initial surgical treatment. *Represents the P value <0.05.
PTC, papillary thyroid carcinoma; s.d., standard deviation.